Abrysvo

News

GSK's RSV shot cleared in US for all adults

GSK is back on level pegging with its rivals in the RSV vaccine category in the US, after getting FDA approval for Arexvy in the 18 to 49 age bracket.

News

Stéphane Bancel, Moderna's chief executive

Moderna's RSV shot gets US nod for use in younger adults

The label for Moderna's RSV vaccine mResvia has been expanded to include adults aged 18 and over in the US, but will that lead to an uptick in sales?

News

There's good news for RSV jab firms at delayed ACIP meeting

GSK and Pfizer could see a resurgence in sales of their RSV vaccines if new recommendations at a CDC expert meeting are confirmed by agency leaders.

News

GSK rides out vaccine sales weakness with cancer, HIV gains

Despite a steep fall-off in sales of RSV vaccine Arexvy last year, GSK has raised its long-term sales forecast to £40 billion in 2031.

News

Alarm bell rings for GSK as US policy dents RSV jab sales

Sales of GSK's respiratory syncytial virus (RSV) vaccine Arexvy slumped 72% in the third quarter of this year, as narrower recommendations on its use in the US started to have an effect.

News

Pfizer gets a leg up in RSV as FDA clears jab for all adults

A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival shots from GSK and Moderna, but it may not make much of a difference

GSK's RSV shot cleared in US for all adults

Moderna's RSV shot gets US nod for use in younger adults

There's good news for RSV jab firms at delayed ACIP meeting

GSK rides out vaccine sales weakness with cancer, HIV gains

Alarm bell rings for GSK as US policy dents RSV jab sales

Pfizer gets a leg up in RSV as FDA clears jab for all adults

FDA approves higher Wegovy dose via 4th priority voucher

Using AI-driven synthetic personas to take your insights fur...

Abrysvo

Editor's Picks